Temporal response of an injectable calcium phosphate material in a critical size defect.

Autor: Landeck JT; Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA, 01605, USA.; Graduate School of Biomedical Sciences, University of Massachusetts Medical School, Worcester, MA, 01605, USA., Walsh WR; Surgical & Orthopaedic Research Laboratories (SORL), Prince of Wales Clinical School, Level 1 Clinical Sciences Building, Prince of Wales Hospital, UNSW Sydney, Sydney, Australia. w.walsh@unsw.edu.au., Oliver RA; Surgical & Orthopaedic Research Laboratories (SORL), Prince of Wales Clinical School, Level 1 Clinical Sciences Building, Prince of Wales Hospital, UNSW Sydney, Sydney, Australia., Wang T; Surgical & Orthopaedic Research Laboratories (SORL), Prince of Wales Clinical School, Level 1 Clinical Sciences Building, Prince of Wales Hospital, UNSW Sydney, Sydney, Australia., Gordon MR; Anika Therapeutics Inc., Bedford, MA, USA., Ahn E; X-Factor Capital, Dover, MA, 02030, USA., White CD; Vertex Pharmaceuticals, 50 Northern Ave, Boston, MA, 02210, USA.
Jazyk: angličtina
Zdroj: Journal of orthopaedic surgery and research [J Orthop Surg Res] 2021 Aug 13; Vol. 16 (1), pp. 496. Date of Electronic Publication: 2021 Aug 13.
DOI: 10.1186/s13018-021-02651-8
Abstrakt: Background: Calcium phosphate-based bone graft substitutes are used to facilitate healing in bony defects caused by trauma or created during surgery. Here, we present an injectable calcium phosphate-based bone void filler that has been purposefully formulated with hyaluronic acid to offer a longer working time for ease of injection into bony defects that are difficult to access during minimally invasive surgery.
Methods: The bone substitute material deliverability and physical properties were characterized, and in vivo response was evaluated in a critical size distal femur defect in skeletally mature rabbits to 26 weeks. The interface with the host bone, implant degradation, and resorption were assessed with time.
Results: The calcium phosphate bone substitute material could be injected as a paste within the working time window of 7-18 min, and then self-cured at body temperature within 10 min. The material reached a maximum ultimate compressive strength of 8.20 ± 0.95 MPa, similar to trabecular bone. The material was found to be biocompatible and osteoconductive in vivo out to 26 weeks, with new bone formation and normal bone architecture observed at 6 weeks, as demonstrated by histological evaluation, microcomputed tomography, and radiographic evaluation.
Conclusions: These findings show that the material properties and performance are well suited for minimally invasive percutaneous delivery applications.
(© 2021. The Author(s).)
Databáze: MEDLINE
Externí odkaz: